An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Codexis, Inc. (NASDAQ: CDXS) will report its Q1 2024 financial results on May 2, 2024. The company will host a conference call and webcast to discuss the results and provide a business update. Participants can access the live webcast on Codexis Investor Relations website.
Codexis, Inc. (NASDAQ: CDXS) comunicherà i risultati finanziari del primo trimestre del 2024 il 2 maggio 2024. L'azienda organizzerà una conferenza telefonica e un webcast per discutere i risultati e fornire un aggiornamento sulle attività aziendali. I partecipanti possono accedere al webcast dal vivo sul sito delle relazioni con gli investitori di Codexis.
Codexis, Inc. (NASDAQ: CDXS) informará sobre sus resultados financieros del primer trimestre de 2024 el 2 de mayo de 2024. La compañía realizará una llamada de conferencia y una transmisión web para discutir los resultados y proporcionar una actualización sobre el negocio. Los participantes pueden acceder a la transmisión web en vivo en el sitio web de Relaciones con Inversores de Codexis.
Codexis, Inc. (NASDAQ: CDXS)는 2024년 5월 2일에 2024년 1분기 재무 결과를 보고할 예정입니다. 회사는 결과를 논의하고 비즈니스 업데이트를 제공하기 위해 컨퍼런스 콜 및 웹캐스트를 주최할 것입니다. 참가자들은 Codexis 투자자 관계 웹사이트에서 생방송 웹캐스트에 접속할 수 있습니다.
Codexis, Inc. (NASDAQ: CDXS) annoncera ses résultats financiers pour le premier trimestre de 2024 le 2 mai 2024. La société organisera une conférence téléphonique et une diffusion web pour discuter des résultats et fournir une mise à jour sur les affaires de l'entreprise. Les participants peuvent accéder à la webdiffusion en direct sur le site des relations avec les investisseurs de Codexis.
Codexis, Inc. (NASDAQ: CDXS) wird die Finanzergebnisse für das erste Quartal 2024 am 2. Mai 2024 bekannt geben. Das Unternehmen wird eine Telefonkonferenz und ein Webcast durchführen, um die Ergebnisse zu diskutieren und ein Geschäftsupdate zu geben. Teilnehmer können den Live-Webcast auf der Investor Relations Webseite von Codexis aufrufen.
Positive
None.
Negative
None.
REDWOOD CITY, Calif., April 18, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the first quarter of 2024 on Thursday, May 2, 2024, following the close of market. Codexis management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the Company’s financial results and provide a business update.
Participants may access the live webcast on the Codexis Investor Relations website, where it will be archived for 90 days. The live call can be accessed by dialing 877-705-2976 (domestic) or 201-689-8798 (international). A telephone replay of the call will be available for 48 hours by dialing 877-660-6853 (domestic) or 201-612-7415 (international), access ID #13726635.
About Codexis Codexis is a leading enzyme engineering company leveraging its proprietary CodeEvolver® technology platform to discover, develop and enhance novel, high-performance enzymes and other classes of proteins. Codexis enzymes solve for real-world challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis™ manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis’ unique enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. For more information, visit https://www.codexis.com.
Media Contact Lauren Musto (650) 421-8205 media@codexis.com
FAQ
When will Codexis report its Q1 2024 financial results?
Codexis will report its Q1 2024 financial results on May 2, 2024.
Where can participants access the live webcast to discuss the financial results?
Participants can access the live webcast on the Codexis Investor Relations website.
What time will the conference call and webcast take place to discuss the financial results?
The conference call and webcast will take place at 4:30 pm Eastern Time.
How long will the webcast be available for viewing after the live event?
The webcast will be archived for 90 days on the Codexis Investor Relations website.
How can participants access the live call for the conference?
Participants can access the live call by dialing 877-705-2976 (domestic) or 201-689-8798 (international).
For how long will the telephone replay of the call be available?
The telephone replay of the call will be available for 48 hours by dialing 877-660-6853 (domestic) or 201-612-7415 (international), access ID #13726635.
codexis, inc. is a leading protein engineering company applying innovative technologies to unlock the power of proteins™. our proprietary codeevolver® technology platform enables the rapid development and production of highly optimized proteins, custom-designed for your application. codexis’ revolutionary approach to protein engineering starts with an understanding of the desired performance specifications and optimizes a protein specifically to fit these requirements. you get precisely the protein you need for the job you want it to do. guided by proprietary artificial intelligence software and advanced high-throughput screening systems, codexis is able to efficiently generate and introduce function-driven mutations to rapidly improve a protein for its target application. since 2002, codexis’ in-house biochemists, biologists and bioinformatics experts have worked closely with our clients to advance the technologies for protein optimization and production, enabling breakthrough develop
